HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis

NASDAQ:HALO • US40637H1095

69.53 USD
+0.31 (+0.45%)
At close: Feb 27, 2026
69.53 USD
0 (0%)
After Hours: 2/27/2026, 8:08:11 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Overall HALO gets a fundamental rating of 7 out of 10. We evaluated HALO against 520 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making HALO a very profitable company, without any liquidiy or solvency issues. A decent growth rate in combination with a cheap valuation! Better keep an eye on HALO. These ratings could make HALO a good candidate for value and quality investing.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year HALO was profitable.
  • In the past year HALO had a positive cash flow from operations.
  • Each year in the past 5 years HALO has been profitable.
  • In the past 5 years HALO always reported a positive cash flow from operatings.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

1.2 Ratios

  • With an excellent Return On Assets value of 12.55%, HALO belongs to the best of the industry, outperforming 94.44% of the companies in the same industry.
  • HALO has a Return On Equity of 649.18%. This is amongst the best in the industry. HALO outperforms 99.81% of its industry peers.
  • HALO's Return On Invested Capital of 25.65% is amongst the best of the industry. HALO outperforms 98.47% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for HALO is above the industry average of 17.87%.
  • The last Return On Invested Capital (25.65%) for HALO is above the 3 year average (20.76%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 12.55%
ROE 649.18%
ROIC 25.65%
ROA(3y)16.77%
ROA(5y)19.55%
ROE(3y)369.08%
ROE(5y)286.14%
ROIC(3y)20.76%
ROIC(5y)19.08%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400 600

1.3 Margins

  • HALO has a better Profit Margin (22.69%) than 94.44% of its industry peers.
  • In the last couple of years the Profit Margin of HALO has declined.
  • HALO has a better Operating Margin (58.45%) than 100.00% of its industry peers.
  • In the last couple of years the Operating Margin of HALO has grown nicely.
  • HALO has a better Gross Margin (83.62%) than 86.78% of its industry peers.
  • HALO's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 58.45%
PM (TTM) 22.69%
GM 83.62%
OM growth 3Y10.06%
OM growth 5Y1.62%
PM growth 3Y-9.5%
PM growth 5Y-14%
GM growth 3Y1.96%
GM growth 5Y-0.04%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • HALO has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, HALO has less shares outstanding
  • The number of shares outstanding for HALO has been reduced compared to 5 years ago.
  • HALO has a worse debt/assets ratio than last year.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • HALO has an Altman-Z score of 3.94. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
  • HALO has a Altman-Z score of 3.94. This is in the better half of the industry: HALO outperforms 69.35% of its industry peers.
  • HALO has a debt to FCF ratio of 6.00. This is a slightly negative value and a sign of low solvency as HALO would need 6.00 years to pay back of all of its debts.
  • The Debt to FCF ratio of HALO (6.00) is better than 91.38% of its industry peers.
  • A Debt/Equity ratio of 43.89 is on the high side and indicates that HALO has dependencies on debt financing.
  • HALO has a Debt to Equity ratio of 43.89. This is amonst the worse of the industry: HALO underperforms 81.99% of its industry peers.
Industry RankSector Rank
Debt/Equity 43.89
Debt/FCF 6
Altman-Z 3.94
ROIC/WACC3.44
WACC7.46%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 4.66 indicates that HALO has no problem at all paying its short term obligations.
  • The Current ratio of HALO (4.66) is comparable to the rest of the industry.
  • HALO has a Quick Ratio of 3.66. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
  • HALO has a Quick ratio (3.66) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.66
Quick Ratio 3.66
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The earnings per share for HALO have decreased by -2.36% in the last year.
  • HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 35.63% yearly.
  • Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 37.55%.
  • HALO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 39.16% yearly.
EPS 1Y (TTM)-2.36%
EPS 3Y22.99%
EPS 5Y35.63%
EPS Q2Q%-119.05%
Revenue 1Y (TTM)37.55%
Revenue growth 3Y28.38%
Revenue growth 5Y39.16%
Sales Q2Q%51.6%

3.2 Future

  • HALO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.28% yearly.
  • HALO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.67% yearly.
EPS Next Y101.78%
EPS Next 2Y54.48%
EPS Next 3Y35.8%
EPS Next 5Y17.28%
Revenue Next Year26.89%
Revenue Next 2Y19.59%
Revenue Next 3Y12.37%
Revenue Next 5Y5.67%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 16.84, the valuation of HALO can be described as correct.
  • Based on the Price/Earnings ratio, HALO is valued cheaply inside the industry as 95.02% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of HALO to the average of the S&P500 Index (27.07), we can say HALO is valued slightly cheaper.
  • HALO is valuated reasonably with a Price/Forward Earnings ratio of 8.34.
  • HALO's Price/Forward Earnings ratio is rather cheap when compared to the industry. HALO is cheaper than 98.08% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.05. HALO is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 16.84
Fwd PE 8.34
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 96.17% of the companies listed in the same industry.
  • HALO's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HALO is cheaper than 95.02% of the companies in the same industry.
Industry RankSector Rank
P/FCF 22.92
EV/EBITDA 11.24
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

  • HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of HALO may justify a higher PE ratio.
  • HALO's earnings are expected to grow with 35.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.17
PEG (5Y)0.47
EPS Next 2Y54.48%
EPS Next 3Y35.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • HALO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (2/27/2026, 8:08:11 PM)

After market: 69.53 0 (0%)

69.53

+0.31 (+0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17
Earnings (Next)05-04
Inst Owners105.85%
Inst Owner Change-19.83%
Ins Owners0.81%
Ins Owner Change0.73%
Market Cap8.18B
Revenue(TTM)1.40B
Net Income(TTM)316.89M
Analysts76
Price Target86.19 (23.96%)
Short Float %11.63%
Short Ratio6.63
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-53.57%
Min EPS beat(2)-110.7%
Max EPS beat(2)3.56%
EPS beat(4)3
Avg EPS beat(4)-18.27%
Min EPS beat(4)-110.7%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)-1.32%
EPS beat(12)9
Avg EPS beat(12)0.23%
EPS beat(16)12
Avg EPS beat(16)2.67%
Revenue beat(2)2
Avg Revenue beat(2)1.65%
Min Revenue beat(2)1.13%
Max Revenue beat(2)2.18%
Revenue beat(4)4
Avg Revenue beat(4)6.95%
Min Revenue beat(4)1.13%
Max Revenue beat(4)12.81%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)8
Avg Revenue beat(12)3.65%
Revenue beat(16)10
Avg Revenue beat(16)2.56%
PT rev (1m)9.56%
PT rev (3m)13.34%
EPS NQ rev (1m)-13.18%
EPS NQ rev (3m)-15.58%
EPS NY rev (1m)-0.27%
EPS NY rev (3m)2.43%
Revenue NQ rev (1m)-2.16%
Revenue NQ rev (3m)-5.22%
Revenue NY rev (1m)3.94%
Revenue NY rev (3m)7.24%
Valuation
Industry RankSector Rank
PE 16.84
Fwd PE 8.34
P/S 5.85
P/FCF 22.92
P/OCF 12.55
P/B 167.51
P/tB N/A
EV/EBITDA 11.24
EPS(TTM)4.13
EY5.94%
EPS(NY)8.33
Fwd EY11.99%
FCF(TTM)3.03
FCFY4.36%
OCF(TTM)5.54
OCFY7.97%
SpS11.88
BVpS0.42
TBVpS-12.87
PEG (NY)0.17
PEG (5Y)0.47
Graham Number6.21
Profitability
Industry RankSector Rank
ROA 12.55%
ROE 649.18%
ROCE 34.76%
ROIC 25.65%
ROICexc 27.31%
ROICexgc 93.59%
OM 58.45%
PM (TTM) 22.69%
GM 83.62%
FCFM 25.55%
ROA(3y)16.77%
ROA(5y)19.55%
ROE(3y)369.08%
ROE(5y)286.14%
ROIC(3y)20.76%
ROIC(5y)19.08%
ROICexc(3y)25.83%
ROICexc(5y)35.19%
ROICexgc(3y)78.99%
ROICexgc(5y)74.81%
ROCE(3y)28.13%
ROCE(5y)25.85%
ROICexgc growth 3Y19.79%
ROICexgc growth 5YN/A
ROICexc growth 3Y19.91%
ROICexc growth 5YN/A
OM growth 3Y10.06%
OM growth 5Y1.62%
PM growth 3Y-9.5%
PM growth 5Y-14%
GM growth 3Y1.96%
GM growth 5Y-0.04%
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 43.89
Debt/FCF 6
Debt/EBITDA 2.37
Cap/Depr 334.74%
Cap/Sales 21.1%
Interest Coverage 71.42
Cash Conversion 72.05%
Profit Quality 112.6%
Current Ratio 4.66
Quick Ratio 3.66
Altman-Z 3.94
F-Score5
WACC7.46%
ROIC/WACC3.44
Cap/Depr(3y)121.97%
Cap/Depr(5y)85.12%
Cap/Sales(3y)8%
Cap/Sales(5y)5.01%
Profit Quality(3y)116.88%
Profit Quality(5y)108.21%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.36%
EPS 3Y22.99%
EPS 5Y35.63%
EPS Q2Q%-119.05%
EPS Next Y101.78%
EPS Next 2Y54.48%
EPS Next 3Y35.8%
EPS Next 5Y17.28%
Revenue 1Y (TTM)37.55%
Revenue growth 3Y28.38%
Revenue growth 5Y39.16%
Sales Q2Q%51.6%
Revenue Next Year26.89%
Revenue Next 2Y19.59%
Revenue Next 3Y12.37%
Revenue Next 5Y5.67%
EBIT growth 1Y48.02%
EBIT growth 3Y41.29%
EBIT growth 5Y41.42%
EBIT Next Year40.15%
EBIT Next 3Y22.4%
EBIT Next 5Y3.88%
FCF growth 1Y-23.82%
FCF growth 3Y14.89%
FCF growth 5Y46.43%
OCF growth 1Y36.01%
OCF growth 3Y39.48%
OCF growth 5Y63.66%

HALOZYME THERAPEUTICS INC / HALO FAQ

Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 7 / 10 to HALO.


Can you provide the valuation status for HALOZYME THERAPEUTICS INC?

ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.


Can you provide the profitability details for HALOZYME THERAPEUTICS INC?

HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 9 / 10.


What is the financial health of HALOZYME THERAPEUTICS INC (HALO) stock?

The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 7 / 10.


Can you provide the expected EPS growth for HALO stock?

The Earnings per Share (EPS) of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 101.78% in the next year.